Characteristics, evaluation and suppression of anti-poly(ethylene glycol) antibody

DOI Web Site Web Site 43 References
  • Shimizu Taro
    Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University
  • Ishida Tatsuhiro
    Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University

Bibliographic Information

Other Title
  • Poly（ethylene glycol）に対する抗体の特性、評価、抑制
  • Poly(ethylene glycol)ニ タイスル コウタイ ノ トクセイ 、 ヒョウカ 、 ヨクセイ

Search this article

Abstract

Modification with PEG(poly(ethylene glycol)), so-called PEGylation, is a golden standard to increase stability of biological medicine. However, PEGylated materials cause anti-PEG antibody after first injection. Then, the anti-PEG antibody induce the accelerated blood clearance(ABC) phenomenon of subsequent dose of PEGylated materials. So far, it has been reported that anti-PEG antibody production occurs not only in experimental animals, but also in human. In addition, characteristics of anti-PEG antibody induced by one PEGylated material differ from that of anti-PEG antibody induced by other PEGylated materials. In order to preserve the merit of PEGylation technology, it is important to understand the correct characteristics of anti-PEG immune response and develop strategy for escaping the immune response. In this review, we show the characteristics, evaluation and suppression of anti-PEG antibody.

Journal

  • Drug Delivery System

    Drug Delivery System 31 (4), 300-307, 2016

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References(43)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top